Low adiponectin levels and increased risk of type 2 diabetes in patients with myocardial infarction - PubMed
. 2014 Nov;37(11):3003-8.
doi: 10.2337/dc14-0932. Epub 2014 Jul 30.
Affiliations
- PMID: 25078899
- DOI: 10.2337/dc14-0932
Low adiponectin levels and increased risk of type 2 diabetes in patients with myocardial infarction
Søren Lindberg et al. Diabetes Care. 2014 Nov.
Abstract
Objective: Patients with acute myocardial infarction (MI) have increased risk of developing type 2 diabetes mellitus (T2DM). Adiponectin is an insulin-sensitizing hormone produced in adipose tissue, directly suppressing hepatic gluconeogenesis, stimulating fatty acid oxidation and glucose uptake in skeletal muscle and insulin secretion. In healthy humans, low plasma adiponectin levels associate with increased risk of T2DM; however, the relationship between adiponectin and T2DM in patients with MI has never been investigated.
Research design and methods: We prospectively included 666 patients with ST-segment elevation MI, without diabetes, treated with percutaneous coronary intervention, from September 2006 to December 2008 at a tertiary cardiac center. Blood samples were drawn before intervention, and total plasma adiponectin was measured in all samples. During follow-up (median 5.7 years [interquartile range 5.3-6.1]) 6% (n = 38) developed T2DM. Risk of T2DM was analyzed using a competing risk analysis.
Results: Low adiponectin levels were associated with increased risk of T2DM (P < 0.001). Even after adjustment for confounding risk factors (age, sex, hypertension, hypercholesterolemia, current smoking, previous MI, BMI, blood glucose, total cholesterol, HDL, LDL, triglyceride, estimated glomerular filtration rate, C-reactive protein, peak troponin I, and proatrial natriuretic peptide), low adiponectin levels remained an independent predictor of T2DM (hazard ratio [HR] 5.8 [2.3-15.0]; P < 0.001). Importantly, plasma adiponectin added to the predictive value of blood glucose, with the combination of high blood glucose and low plasma adiponectin, vastly increasing the risk of developing T2DM (HR 9.6 [3.7-25.3]; P < 0.001).
Conclusions: Low plasma adiponectin levels are independently associated with increased risk of T2DM in patients with MI and added significantly to the predictive value of blood glucose.
© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
Similar articles
-
Adiponectin, type 2 diabetes and cardiovascular risk.
Lindberg S, Jensen JS, Bjerre M, Pedersen SH, Frystyk J, Flyvbjerg A, Galatius S, Jeppesen J, Mogelvang R. Lindberg S, et al. Eur J Prev Cardiol. 2015 Mar;22(3):276-83. doi: 10.1177/2047487313514894. Epub 2013 Nov 21. Eur J Prev Cardiol. 2015. PMID: 24265290
-
Lindberg S, Pedersen SH, Møgelvang R, Bjerre M, Frystyk J, Flyvbjerg A, Galatius S, Jensen JS. Lindberg S, et al. Am J Cardiol. 2012 Feb 15;109(4):492-6. doi: 10.1016/j.amjcard.2011.09.041. Epub 2011 Nov 19. Am J Cardiol. 2012. PMID: 22105783
-
Li Y, Yatsuya H, Iso H, Toyoshima H, Tamakoshi K. Li Y, et al. Diabetes Metab Res Rev. 2012 May;28(4):349-56. doi: 10.1002/dmrr.2277. Diabetes Metab Res Rev. 2012. PMID: 22228701
-
Lipids and glucose in type 2 diabetes: what is the cause and effect?
Boden G, Laakso M. Boden G, et al. Diabetes Care. 2004 Sep;27(9):2253-9. doi: 10.2337/diacare.27.9.2253. Diabetes Care. 2004. PMID: 15333497 Review. No abstract available.
-
Adiponectin: Probe of the molecular paradigm associating diabetes and obesity.
Ghoshal K, Bhattacharyya M. Ghoshal K, et al. World J Diabetes. 2015 Feb 15;6(1):151-66. doi: 10.4239/wjd.v6.i1.151. World J Diabetes. 2015. PMID: 25685286 Free PMC article. Review.
Cited by
-
An adiponectin-S1P autocrine axis protects skeletal muscle cells from palmitate-induced cell death.
Botta A, Elizbaryan K, Tashakorinia P, Lam NH, Sweeney G. Botta A, et al. Lipids Health Dis. 2020 Jul 1;19(1):156. doi: 10.1186/s12944-020-01332-5. Lipids Health Dis. 2020. PMID: 32611437 Free PMC article.
-
Rajaraman B, Ramadas N, Krishnasamy S, Ravi V, Pathak A, Devasena CS, Swaminathan K, Ganeshprasad A, Kuppuswamy AA, Vedantham S. Rajaraman B, et al. Mol Cell Biochem. 2019 Jun;456(1-2):179-190. doi: 10.1007/s11010-019-03503-0. Epub 2019 Feb 14. Mol Cell Biochem. 2019. PMID: 30767098
-
Adiponectin for the treatment of diabetic nephropathy.
Lee JY, Yang JW, Han BG, Choi SO, Kim JS. Lee JY, et al. Korean J Intern Med. 2019 May;34(3):480-491. doi: 10.3904/kjim.2019.109. Epub 2019 Apr 30. Korean J Intern Med. 2019. PMID: 31048658 Free PMC article. Review.
-
Tissue-specific role and associated downstream signaling pathways of adiponectin.
Roy B, Palaniyandi SS. Roy B, et al. Cell Biosci. 2021 Apr 26;11(1):77. doi: 10.1186/s13578-021-00587-4. Cell Biosci. 2021. PMID: 33902691 Free PMC article. Review.
-
Wang Y, Meng RW, Kunutsor SK, Chowdhury R, Yuan JM, Koh WP, Pan A. Wang Y, et al. Sci Rep. 2018 Jan 10;8(1):406. doi: 10.1038/s41598-017-18709-9. Sci Rep. 2018. PMID: 29321603 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials